Michael Aaron Kelly - 30 Jun 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
30 Jun 2021
Transactions value $
$0
Form type
4
Date filed
01 Jul 2021, 19:07
Previous filing
14 Jun 2021
Next filing
12 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +4.61K $0.00 4.61K 30 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (Right to Buy) Award $0 +22.8K $0.00 22.8K 30 Jun 2021 Common Stock 22.8K $4.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.